Benitec Biopharma Inc. (BNTC) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$11.61

From 52W high−33.29%

Volume422989.00

Market cap$384.41M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$11.61

From 52W high

−33.29%

Volume

422989.00

Market cap

$384.41M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.0x

P/E (TTM)

—

RSI (14)

36.4

MomentumView details →

1D Return

−2.99%

YTD Return

−17.33%

SummaryUpdated Jun 1, 2026

Benitec Biopharma Inc. (NASDAQ:BNTC) is a development-stage biotechnology company founded in 1995 and headquartered in Hayward, California. The company went public in 2014 and focuses on developing novel genetic medicines using proprietary DNA-directed RNA interference (ddRNAi) technology. As a clinical-stage biotech firm, Benitec has built its pipeline around treating rare genetic diseases and chronic viral infections through innovative gene therapy approaches.

Ask drillr about Benitec Biopharma Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−4.0x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.2x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−25.73%

ROA (TTM)

−24.94%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

+37.97%

FCF YoY

+28.59%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+6.67%

EBITDA YoY

−13.88%

MomentumView details →

1D Return

−2.99%

YTD Return

−17.33%

1Y Return

−17.21%

RSI (14)

36.4

vs 50D SMA

−10.53%

vs 200D SMA

−7.57%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

34.00x

Quick Ratio

34.00x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.26

EPS Surprise

1.62%

Beats (12Q)

7/12

Next Q EPS Est

−$0.26

Avg Surprise (4Q)

9.21%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−45.55M

Op. CF (TTM)

−16.98M

Next earningsNov 13, 2026 →

Latest newsMore news →

Benitec Biopharma released its full year 2026 financial results and provided an operational update, reporting approximately $180 million in cash as of June 30, 2026.6d ago

Similar companies

BridgeBio Oncology Therapeutics Inc.BBOT Cypherpunk Technologies Inc.CYPH Prelude Therapeutics IncorporatedPRLD Galectin Therapeutics Inc.GALT Larimar Therapeutics, Inc.LRMR Fennec Pharmaceuticals Inc.FENC Find similar companies →

Latest newsMore news →

Benitec Biopharma released its full year 2026 financial results and provided an operational update, reporting approximately $180 million in cash as of June 30, 2026.6d ago